Biogen Begins Its Oncology Sell-Off, Parting With Two Kinase Inhibitors
This article was originally published in The Pink Sheet Daily
New CEO George Scangos pledged in November to return Biogen Idec to its neurology and immunology roots. This is the first divestment deal under the new regime.
You may also be interested in...
Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.
The highly competitive multiple sclerosis market is in flux. With the US launch in October 2010 of Novartis AG's Gilenya, the first oral disease-modifying therapy for MS, patients and physicians have a more convenient once-daily therapy that looks to be as efficacious as first line injectables. But uncertainty concerning Gilenya's safety- not to mention the medicine's high price tag - means ample room exists for additional products in the MS armamentarium. To better understand how prescribers view the rapidly changing MS landscape, IN VIVO and Gerson Lehman Group conducted a survey of physicians in late January.
Thanks to a November restructuring that refocused the company around its historic strength in neurology and the hiring of two critical executives, Biogen believes it can grow beyond its warhorses Avonex and Tysabri